A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

The diagnostic accuracy (AUROC) for the diagnosis of significant fibrosis (F≥2) for ELF and FibroTest was 0.78 (95%-CI: 0.67–0.89) and 0.69 (95%-CI: 0.57–0.82), respectively (s. figure 1).

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

AdAlta Ltd. (AU:1AD) has released an update. AdAlta Limited is bolstering its leadership team with the appointment of Kevin Lynch as Consultant Chief Medical Officer for its AdCella subsidiary ...

Peyronie's and Dupuytren's diseases are benign but are source of significant functional impairment leading to considerable suffering. In this study, the aim is to investigate the association between ...

In late June of last year, I was told I had three tumors that tested positive for triple negative, aggressive, invasive breast cancer. It was different from the Stage 1, HR-positive, HER2-negative ...

I was curious, however, [to explore this in] women who are keeping their bladders, so women that either have non–muscle-invasive bladder cancer and are receiving intravesical treatment, or women that ...

Gilead is with­draw­ing the ac­cel­er­at­ed ap­proval for its block­buster an­ti­body-drug con­ju­gate Trodelvy for blad­der can­cer af­ter it failed to im­prove sur­vival odds ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

In May, Gilead Sciences announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.